J&J bets $2.2B on Ollin’s vision loss drug
The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.